Small-molecule-directed mpl signaling can complement growth factors to selectively expand genetically modified cord blood cells.
Efforts toward achieving gene therapy for blood disorders are plagued by low rates of gene transfer into hemopoietic stem cells. Recent studies suggest that this obstacle can be circumvented using selection. One way to achieve selection employs genes that encode receptor-bearing fusion proteins capable of inducing cell growth in response to drugs called chemical inducers of dimerization (CIDs). We have previously shown that genetically modified marrow cells from mice can proliferate for up to a year in culture in response to CID-initiated signals arising from the thrombopoietin receptor (mpl). The sustained growth observed in mouse hemopoietic cells results from an mpl-induced self-renewal of multipotential hemopoietic progenitor cells. In contrast, human hemopoietic cells proliferate only transiently in response to the mpl signal (from differentiation of transduced erythroid and megakaryocytic progenitors), while human myeloid progenitors fail to respond. Here, we show that myeloid progenitors from human cord blood can be induced to proliferate and/or differentiate in response to the mpl signal by providing additional signals via a combination of growth factors. These findings are relevant for the eventual clinical application of CID-regulated cell therapy.
Richard
Robert E
RE
Division of Hematology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Blau
C Anthony
CA
D018952:Antigens, CD34 / Q000096:biosynthesis / Q000276:immunology; D001854:Bone Marrow Cells / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D002478:Cells, Cultured; D005312:Fetal Blood / Q000737:chemistry / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D005822:Genetic Vectors; D049452:Green Fluorescent Proteins; D006133:Growth Substances / Q000502:physiology*; D006801:Humans; D018189:Immunomagnetic Separation / Q000379:methods; D008164:Luminescent Proteins / Q000096:biosynthesis / Q000235:genetics; D023461:Myeloid Progenitor Cells / Q000187:drug effects / Q000502:physiology* / Q000821:virology; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D018121:Receptors, Cytokine / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D053628:Receptors, Thrombopoietin; D012190:Retroviridae / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D016559:Tacrolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D014161:Transduction, Genetic
C463061:AP20187; D018952:Antigens, CD34; D006133:Growth Substances; D008164:Luminescent Proteins; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; D049452:Green Fluorescent Proteins; D016559:Tacrolimus